Search
Now showing items 1-2 of 2
In honour of Professor Jackie Ying, recipient of the Journal of Drug Targeting's Lifetime Achievement Award�for 2020
(
Taylor and Francis Ltd
, 2020 , Article)
[No abstract available]
Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
(
Taylor and Francis Ltd
, 2020 , Article)
Objectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize ...